Research programme: gene regulation therapeutics - Sangamo Therapeutics/Shire

Drug Profile

Research programme: gene regulation therapeutics - Sangamo Therapeutics/Shire

Alternative Names: hFVIII; SB-FVIII; ZFN genome editing therapeutics - Sangamo/Shire; ZFP therapeutics - Sangamo/Shire

Latest Information Update: 11 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sangamo BioSciences; Shire
  • Developer Sangamo Therapeutics
  • Class Gene therapies; Transcription factors; Zinc finger DNA binding proteins
  • Mechanism of Action Blood coagulation factor modulators; DNA binding protein modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haemophilia A; Huntington's disease

Most Recent Events

  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
  • 07 Dec 2016 Preclinical development for Huntington's disease and Haemophilia A is ongoing in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Haemophilia-A in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top